SCOTUS: No standing in challenge to mifepristone changes (FDA v. AHM)
The Supreme Court unanimously held the plaintiffs lacked Article III standing to challenge FDA’s 2016/2021 actions on mifepristone, leaving the agency’s changes in place. Justice Kavanaugh delivered the opinion, with the Court finding that the Alliance for Hippocratic Medicine failed to demonstrate a concrete injury that would grant them legal standing to challenge the FDA’s regulation of the abortion medication. This ruling preserves current access to mifepristone through telemedicine and pharmacies.
Key Actors
Sources (4)
- FDA v. Alliance for Hippocratic Medicine, 602 U.S. ___ (2024) (2024-06-13)
- Food and Drug Administration v. Alliance for Hippocratic Medicine (2024-06-13)
- Attorney General Merrick B. Garland Statement on the Supreme Court's Decision in FDA v. Alliance for Hippocratic Medicine (2024-06-13)
- Looking to the Future: Implications of the SCOTUS Ruling on Mifepristone (2024-06-13)
Help Improve This Timeline
Found an error or have additional information? You can help improve this event.
Edit: Opens GitHub editor to submit corrections or improvements via pull request.
Suggest: Opens a GitHub issue to propose a new event for the timeline.